Research programme: TDP1 and TOP1 inhibitors - Aphios/National Cancer InstituteAlternative Names: APH 0804; Tdp-1 inhibitors; Tyrosyl-DNA phosphodiesterase 1 protein inhibitors
Latest Information Update: 06 Jan 2015
At a glance
- Originator Aphios Corporation; National Cancer Institute (USA)
- Mechanism of Action DNA topoisomerase I inhibitors; TDP1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 06 Jan 2015 Early research is ongoing in USA
- 01 Apr 2009 Early research in Cancer in USA (unspecified route)